Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $5.31 1.6140 +43.62%
ISIS $65.98 6.4300 +10.80%
ARIA $7.22 0.6100 +9.23%
ZIOP $4.64 0.3700 +8.67%
EPZM $19.85 1.4900 +8.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.55 -4.3000 -39.63%
PARD $0.15 -0.0180 -10.59%
GTXI $0.90 -0.0699 -7.21%
XLRN $38.21 -2.2700 -5.61%
CBMG $13.00 -0.6900 -5.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Drug Hope For Aggressive Breast Cancer

(Sydney Morning Herald) June 2, 2011 - A new Australian discovery could lead to the first ever drug treatment for people battling the most aggressive form of breast cancer.
read article 

Dana-Farber Scientists Identify Overactive Genes in Aggressive Breast Cancers

(Dana-Farber) June 2, 2011 - Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.
read press release 

Ziopharm Seeks Lower Cancer Drug Prices

(Reuters) June 1, 2011 - Ziopharm Oncology Inc's Chief Executive Jonathan Lewis has an idea that could shake up the biotechnology business -- produce less expensive new cancer drugs.
read article 

J&J’s Prostate Cancer Drug Extends Life While Spurring $5 Billion Market

(Bloomberg) June 2, 2011 - Dennis Prestholdt credits the past three years of his life to Johnson & Johnson’s Zytiga, the first prostate cancer pill to win U.S. marketing approval in a family of treatments that offer new ways to stymie the male hormones that fuel tumor growth.
read article 

Bristol-Myers, Roche Agree To Study Skin Cancer Drug Combo

(NASDAQ/Dow Jones Newswires) June 2, 2011 - Bristol-Myers Squibb Co. and Roche Holding AG agreed to study how a combination of their melanoma drugs work in treating patients with a specific genetic mutation.
read article 

Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival

(MD Anderson) June 1, 2011 - A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.
read press release 

HHS Proposes Privacy Rule on Medical Records

(Reuters) May 31, 2011 - Patients could obtain a list of everyone who has accessed their electronic medical record under a rule proposed on Tuesday by the Department of Health and Human Services.
read article 

2 Studies Examine Syndrome of Fatigue

(New York Times) May 31, 2011 - In a blow to patients with chronic fatigue syndrome, two new studies published on Tuesday raised serious doubts about earlier reports that the disabling disease is linked to infection with XMRV, a poorly understood retrovirus.
read article 

Linking Disease Markers to Medical Condition Often Exaggerated, Study Says

(Bloomberg) June 1, 2011 - Studies that link genes and other biological markers to medical conditions such as heart disease or colon cancer may exaggerate the ties, casting doubt on some decisions doctors make for their patients, researchers said.
read article 

FDA Investigates Possible Increased Blood Clot Risk From Some New Birth Control Pills

(Washington Post/The Checkup blog) June 1, 2011 - The Food and Drug Administration is investigating concerns that several new birth control pills may increase the risk for potentially life-threatening blood clots more than older versions.
read article (free registration required) 

Government to Lower Prices, Ease Rules on Health Plans For People With Preexisting Conditions

(Los Angeles Times) June 1, 2011 - The Obama administration, expanding a program created by the new healthcare law, reduces premiums on preexisting condition insurance plans and loosens restrictions on who can sign up for them.
read article (free registration required) 

Surgery Not Option For Carter’s Tumors

(New York Times) May 31, 2011 - Gary Carter was diagnosed on Tuesday as having glioblastoma, an aggressive, fast-moving brain cancer that that will be treated with radiation and chemotherapy, but not with surgery, according to a statement from the Preston Robert Tisch Brain Cancer Center at Duke University Medical Center, where biopsies of the cancer were tested.
read article 

More Than 600 NCCN Chemotherapy Order Templates Now Available From NCCN to Enhance Patient Safety

(Reuters) June 1, 2011 - NCCN launched a complete library of NCCN Chemotherapy Order Templates, including more than 600 peer-reviewed and evidence-based chemotherapy regimens to enhance patient safety by standardizing care.
read article 

URMC Studies Quality of Doc-Patient Conversations About Cancer

(URMC) June 1, 2011 - A $2.9 million University of Rochester Medical Center research project will test a powerful new intervention to improve the quality of discussions among oncologists, patients, and families in the context of incurable cancer, and to promote patient- and family-centered care.
read press release 

ASCO Launches CancerProgress.Net, An Interactive Journey Through 40 Years Of Progress in Cancer Research and Patient Care

(ASCO) May 31, 2011 - The American Society of Clinical Oncology (ASCO) today launched CancerProgress.Net, a dynamic website demonstrating four decades of progress against cancer.
read press release 

Failure to E-Prescribe and Report by June 30 Means Medicare Penalties

(ASCO in Action) May 31, 2011 - CCHIT Certification for Oncology Electronic Health Records (EHRs); ASCO Sponsoring IOM Workshop to Address Development of Combination Investigations Cancer Therapies; Members of Congress Ask Appropriations Committee to Protect NIH Funding; Guidance on Purchasing Drugs in Short Supply; Senate Passes Cancer Research Resolution.
read article 

ApoCell Launches Revolutionary Circulating Cancer Cell Detection System

(iStockAnalyst) June 1, 2011 - ApoCell, Inc. announced today that it has completed the first prototype to commercialize a revolutionary technology that improves the detection of more types of cancer cells circulating in the blood, including rare cell types that have previously gone undetected.
read article 

Cancer Costs Highest For Individually Insured

(Reuters) May 31, 2011 - One of every seven cancer patients spends more than 20 percent of his income on health care and insurance, according to a new study from federal researchers.
read article 

IPSOGEN to Present Two Studies on the Genomic Grade Test at ASCO 2011 in Chicago, Ill, USA

(Ipsogen) May 30, 2011 - IPSOGEN SA today announces that two studies on the Genomic Grade test will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA.
download pdf 

GlobeImmune Reports Positive Results For Two Therapeutic Vaccines, GI-4000 and GI-6207

(MSNBC) June 1, 2011 - GlobeImmune Inc. today presented safety and immunogenicity data from two clinical studies of therapeutic vaccines based on the Company's Tarmogen® technology.
read article 

Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)

(Yahoo! Finance) June 1, 2011 - S*BIO Pte Ltd today announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens.
read article 

Response Genetics Announces Presentation of Lung Cancer and Esophageal Cancer Study Results at 2011 American Society of Clinical Oncology Annual Meeting

(TheStreet) June 1, 2011 - Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3 to June 7, 2011.
read article 

Bavarian Nordic Announces Presentation of PROSTVAC® Data at the 2011 ASCO Annual Meeting

(Bavarian Nordic) June 1, 2011 - Bavarian Nordic A/S today announced that investigators from the National Cancer Institute are presenting at the 2011 ASCO Annual Meeting in Chicago data from a study with PROSTVAC® entitled "Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer".
read press release 

Argos Therapeutics' Arcelis Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

(Yahoo! Finance) June 1, 2011 - Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes.
read article 

Phase II Study Results Showed Eisai’s Lenvatinib (E7080) Demonstrated an Objective Response Rate of 59% in Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer

(iStockAnalyst) June 1, 2011 - Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai’s lenvatinib (USAN) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
read article